NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.
Shawnna A. Ogden ; John T. Ludlow ; Khalid Alsayouri .
Last Update: October 7, 2022 .
The DTaP vaccine is administered to children from 6 weeks to 6 years of age to provide immunization against diphtheria, tetanus, and pertussis. This activity outlines the DTaP vaccine's indications, actions, and potential adverse effects as a valuable agent against these diseases. This activity will highlight the mechanism of action, administration, adverse effects, contraindications, and monitoring pertinent to healthcare team members in managing vaccine-preventable diseases.
Assess the pathophysiologies of diphtheria, tetanus, and pertussis. Identify the components of the DTaP vaccine, dosing, and injection site. Evaluate the recommendations of when to administer the DTaP vaccine.Communicate interprofessional team strategies for improving care coordination and communication to advance immunization against diphtheria, tetanus, and pertussis and improve outcomes.
The DTaP vaccine series is recommended to help protect against diphtheria, tetanus, and pertussis in infants and young children. Individuals susceptible to these vaccine-preventable diseases can develop life-threatening complications and even death. Since the development of universal vaccines in the 1940s, the number of reported cases of diphtheria, tetanus, and pertussis has declined in the United States.
Tetanus is an infectious disease caused by neurotoxins produced by the gram-positive bacillus Clostridium tetani. The heat-resistant spores of the bacteria enter the body at mucous membranes or a breach in the skin. Toxins are formed, including a highly potent toxin called tetanospasmin. This toxin interferes with the release of neurotransmitters in the central nervous system, leading to unopposed muscle contraction and spasms. There is no person-to-person transmission of C. tetani.[1][2]
Moreover, diphtheria results from infection with toxin-producing strains of Corynebacterium diphtheriae, a gram-positive bacillus. The disease is transmissible from person to person by droplets or close contact. The bacteria can multiply and produce the diphtheria toxin in the nasopharynx region, mucous membranes, or skin lesions. Early symptoms can include malaise, sore throat, and low-grade fever. A classic feature of respiratory diphtheria is a gray-colored pseudo-membrane that firmly adheres to the mucosal lining of the nasopharynx, tonsils, or larynx. This pseudo-membrane can extend further into the nasal cavity or larynx, obstructing the airways. Cardiac and neurological complications can occur once the toxin reaches the bloodstream. Respiratory droplets or close contact can transmit diphtheria.[1][3]
Pertussis is a respiratory disease, also known colloquially as whooping cough, caused by the gram-negative bacillus Bordetella pertussis. The disease characteristically has 3 stages: catarrhal, paroxysmal, and convalescent. The catarrhal stage includes symptoms of coryza, mild cough, and low-grade fever. Around 1 to 2 weeks, the infected person enters the paroxysmal stage with symptoms of spasmodic coughing, posttussive vomiting, and inspiratory whoop. Symptoms slowly improve in the convalescent stage but can last for weeks to months. B. pertussis is transmittable through aerosolized droplets generated by coughing or sneezing. People are most infectious at the catarrhal stage or the beginning of the paroxysmal stage.[1][4]
The DTaP vaccine is a combination of diphtheria, tetanus, and pertussis. It comprises diphtheria, tetanus toxoids (inactivated toxins), and acellular pertussis antigens. The tetanus component of the vaccine is about 5 to 10 levels of flocculation units of manufactured tetanus toxoid. The diphtheria component is a manufactured diphtheria toxoid of about 15 to 25 levels of flocculation units. The acellular pertussis component of a DTaP vaccine consists of manufactured pertussis antigens called pertussis toxin, filamentous haemagglutinin, pertactin, and fimbriae type 2 and 3.[1] The vaccine produces an active immune response in the body by developing antibodies and antitoxins against the toxoids and acellular pertussis antigens. Two single DTaP vaccines are available in the United States and approved by the FDA.
The CDC’s Advisory Committee on Immunization Practices (ACIP) recommends administering the DTaP 5-dose vaccine series for children 6 weeks continuing through to 6 years of age.[5] Routine dose recommendations are for the following ages:
Two months: minimum age of 6 weeks Four months: the second dose should be given at least 4 weeks after the first Six months: the third dose should be given at least 4 weeks after the secondFifteen through eighteen months: The minimum age for the fourth dose is 12 months, and it should be given at least 6 months after the third dose. It may be counted as valid if given at least 4 months after the third dose and the child was at least 12 months old.
Four through 6 years: the minimum age for the fifth dose is 4 years old. The dose should be given at least 6 months after the fourth dose.
The DTaP dose is 0.5 mL and given intramuscularly. The preferred intramuscular injection site for infants to 2 years of age is the anterolateral aspect of the thigh. For children 3 years of age and older, the preferred site is the deltoid muscle.[1] DTaP vaccines can also be available in combination with other childhood vaccines. Children unimmunized or incompletely immunized should receive catch-up immunizations. This process is possible with minimal intervals between doses.
Dose 1 to dose 2 - 4 weeks Dose 2 to dose 3 - 4 weeks Dose 3 to dose 4 - 6 months; the minimum age for dose 4 is 12 months. Dose 4 to dose 5 - 6 monthsDTaP is approved during the last 3 months of pregnancy to prevent pertussis in infants under 2 months old.
Whole-cell pertussis vaccines, or DTP vaccines, were commonly associated with local adverse events, including swelling, redness, and pain at the injection site. DTaP vaccines replaced DTP vaccines in the 1990s to reduce the number of these common adverse events. Less common adverse events for pertussis vaccines are seizures, hypotonic-hyporesponsive episodes, and prolonged crying.[1][4] Vaccines with tetanus toxoids can cause brachial neuritis based on case reports and studies reviewed by the World Health Organization and ACIP. The cases can be severe but are rare, and brachial neuritis is usually self-limited.[1][2] ACIP has reviewed several studies regarding the simultaneous administration of DTaP with other vaccines. There may be an increased risk of febrile seizures within 24 hours when administering the inactivated influenza vaccine and the pneumococcal 13-valent conjugate vaccine or the DTaP vaccine. The overall risk for febrile seizures is small with any combination of vaccines. Therefore, the ACIP recommends a simultaneous administration of these vaccines.[1]
Severe allergic reactions or anaphylaxis after administration of the DTaP vaccine or vaccine component is considered a contraindication. Encephalopathy (coma, a decreased level of consciousness, or prolonged seizures) that occurs within 7 days of DTaP administration and with no identifiable cause is also a contraindication. Pregnancy should not be considered a contraindication to DTaP vaccination.[6][7][8]
ACIP reviewed studies that showed children developed a significant antibody response and antitoxin levels of the diseases after 3 to 4 doses of either Infanrix or Daptacel. The Vaccine Adverse Event Reporting System and Vaccine Safety Datalink surveyed any adverse events with the acellular pertussis vaccine in the United States. Overall, the studies support the safety of DTaP.[1] Clinicians should defer vaccines with pertussis components in infants or children with suspected or evolving neurological disease, including seizures. Vaccination with pertussis components can begin or resume upon establishing a treatment regimen, or the condition has stabilized.[1] An Arthus reaction (type III hypersensitivity reaction) can occur after administering vaccines with diphtheria toxoids or tetanus toxoids.[9] Symptoms of the reaction include severe pain, swelling, induration, edema, hemorrhage, and occasionally necrosis. The reaction is rare after vaccine administration and resolves over time. An Arthus reaction is not a contraindication to the DTaP vaccine, but any vaccines with tetanus toxoids should be administered every 10 years.[1]
There is no known antidote or treatment for the DTaP vaccine. Anaphylaxis can occur but is extremely rare. The reaction is treatable with an intramuscular injection of epinephrine.[10]
Vaccine coverage is considered high among infants, children, and adolescents, but clinical data shows that adults have reduced immunity. Vaccine coverage declines with increasing age, resulting from waning immunity or non-vaccination. Vaccines with acellular pertussis do not protect for as long as the prior whole-cell pertussis vaccines. In 2005, the ACIP recommended that adolescents and adults over 10 receive a single dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (TdaP) vaccine. After receiving Tdap, adolescents and adults recommend receiving a booster dose of tetanus and diphtheria toxoids (Td) vaccine every 10 years or when indicated for wound management.
In 2012, ACIP recommended a dose of Tdap for women during each pregnancy to reduce the burden of pertussis in infants. Clinical studies indicated that newborn infants of mothers vaccinated during pregnancy had higher concentrations of pertussis antibodies at birth compared to newborns of unvaccinated mothers during pregnancy. In various healthcare settings, exposure to pertussis can occur to healthcare providers, patients, or hospital visitors. Depending on the approach, managing exposure or pertussis outbreak can be complicated and costly. Postexposure prophylaxis is recommended for healthcare personnel in contact with persons at risk for pertussis. This prophylaxis includes antibiotic treatment with a macrolide such as azithromycin and immediate evaluation of persons with an illness that presents with a cough.
Vaccination programs, in general, require an interprofessional team approach. The treating physician (MD, DO, NP, or PA) orders these, often administered by nursing staff. Pharmacists assist in dose preparation and must know the vaccination schedules or have access to them; many states permit pharmacists to administer vaccines subject to age limitations. This scope of practice for pharmacists continues to expand, depending on the state.[11] To be sure, all healthcare team members should familiarize themselves thoroughly with the various vaccination schedules. Nursing is in the best position to monitor for adverse events or allergic reactions, which, while rare, can occur. These events should be reported to the physician immediately. Only through this type of collaborative interprofessional care can tetanus/diphtheria/pertussis vaccines be administered most effectively for optimal results.
Liang JL, Tiwari T, Moro P, Messonnier NE, Reingold A, Sawyer M, Clark TA. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2018 Apr 27; 67 (2):1-44. [PMC free article : PMC5919600 ] [PubMed : 29702631 ]
Tetanus vaccines: WHO position paper – February 2017. Wkly Epidemiol Rec. 2017 Feb 10; 92 (6):53-76. [PubMed : 28185446 ]
Diphtheria vaccine: WHO position paper – August 2017. Wkly Epidemiol Rec. 2017 Aug 04; 92 (31):417-35. [PubMed : 28776357 ]
Pertussis vaccines: WHO position paper - September 2015. Wkly Epidemiol Rec. 2015 Aug 28; 90 (35):433-58. [PubMed : 26320265 ]
Robinson CL, Bernstein H, Romero JR, Szilagyi P. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2019. MMWR Morb Mortal Wkly Rep. 2019 Feb 08; 68 (5):112-114. [PMC free article : PMC6366676 ] [PubMed : 30730870 ]
Sur DKC, Chande ND. Immunizations in Pregnancy: Updated Recommendations. Am Fam Physician. 2020 Aug 15; 102 (4):205-206. [PubMed : 32803926 ]
Cappozzo F, Dal Zotto A, Scollo M, Bernardini D, Maria Dal Zotto A, Bonvecchio L, Tognetto G, Marinangeli S, Negrello C, Lanza P, Cocco A, Falivene P, Vianello L, Di Caprio A, Gabutti G, Saugo M. dTap vaccination uptake during pregnancy: Pregnant women-focused and health professionals-focused predictors in the Veneto Region (Italy). Vaccine. 2021 Nov 16; 39 (47):6913-6919. [PubMed : 34711438 ]
Layton JB, Butler AM, Li D, Boggess KA, Weber DJ, McGrath LJ, Becker-Dreps S. Prenatal Tdap immunization and risk of maternal and newborn adverse events. Vaccine. 2017 Jul 24; 35 (33):4072-4078. [PMC free article : PMC5546155 ] [PubMed : 28669620 ]
Wang MH, Hu A, Lee YS, Lai CC. Arthus Reaction. J Emerg Med. 2019 Apr; 56 (4):450-451. [PubMed : 30826085 ]
Moro PL, Perez-Vilar S, Lewis P, Bryant-Genevier M, Kamiya H, Cano M. Safety Surveillance of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccines. Pediatrics. 2018 Jul; 142 (1) [PMC free article : PMC6476554 ] [PubMed : 29866795 ]
Echtenkamp CA, Lampkin SJ, Hassan AK. Pharmacists' Attitudes and Practices Regarding Tetanus, Diphtheria and Pertussis (Tdap) Vaccination in Pregnancy and Surrounding Newborns. Pharmacy (Basel). 2018 Apr 25; 6 (2) [PMC free article : PMC6025264 ] [PubMed : 29693570 ]
Disclosure: Shawnna Ogden declares no relevant financial relationships with ineligible companies.
Disclosure: John Ludlow declares no relevant financial relationships with ineligible companies.
Disclosure: Khalid Alsayouri declares no relevant financial relationships with ineligible companies.
